You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.3

An innovative treatment for your patients living with HIV

Bar chart image
Powerful, Durable Efficacy4,5
HBR shield image
High Barrier to Resistance4
Pill bottle image
TDF, TAF and ABC Free4

Dovato is Recommended in Treatment Guidelines

EACS Guidelines 2023

Recommended as an initial regimen for treatment-naïve patients and as a switch strategy for virologially suppressed patients6

  • Requirements for treatment-naïve patients:
    • HBsAG negative
    • HIV viral load <500,000 copies/mL

DHHS Guidelines 2023

Recommended as an initial regimen for most PLHIV (AI)* as a good option for virologically suppressed patients who have no evidence of resistance to either drug7

  • Exclusions for treatment-naïve patients:
    • HIV viral load >500,000 copies/mL
    • HBV co-infection
    • Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available.

*Rating of recommendations: A= strong; B= moderate; C= optional. Rating of evidence: I= data from randomised controlled trials; II= data from well-designed non-randomised trials, observational cohort studies with long-term clinical outcomes, relative bioavailability / bioequivalence studies, or regimen comparisons from randomised switch studies; III= expert opinion.7


  1. Montaner JS, Wood E, Kerr T et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndro. 2010;55 Suppl. 1:5
  2. Eisinger RW, Dieffenbach CW, Fauci AS. HIV VIral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321(5):451-452.
  3. Dovato Summary of Product Characteristics. Available at: Last Accessed January 2024.
  4. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-navie adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquired Immune Defic Syndr. 2020;83(3):310-318.
  5. Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomised noninferioity TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243.
  6. European AIDS Clinical Society Guidelines version 12.0, October 2023. Accessed January 2024. Available at:
  7. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Last Accessed January 2024. Updated: September 21, 2022. Available at:


Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: January 2024 PM-IE-DLL-WCNT-200015